| Description | LJ-001 shows broad-spectrum activity against virtually all enveloped RNA and DNA viruses. LJ001 inhibits the infection of transmissible gastroenteritis virus (TGEV) and porcine delta coronavirus (PDCoV). |
| In vitro | In ST cells, LJ001 (12.5 µM) decreases the N-protein expression of TGEV and PDCoV and the gene mRNA expression in a time-dependent manner. LJ001 shows activities against HIV, HCV, influenza, Ebola, poxviruses and arenaviruses[3]. |
| In vivo | In female BALB/c mice, oral gavage and intraperitoneal administration of LJ001 (20-50 mg/kg) shows no toxicity except a slight elevation in serum cholesterol levels[4]. |
| Synonyms | LJ 001, LJ001 |
| molecular weight | 327.42 |
| Molecular formula | C17H13NO2S2 |
| CAS | 851305-26-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 3.27 mg/mL (10 mM) |
| References | 1. De Clercq E. Highlights in antiviral drug research: antivirals at the horizon. Med Res Rev. 2013 Nov;33(6):1215-48. doi: 10.1002/med.21256. Epub 2012 May 2. Review. PubMed PMID: 22553111. 2. De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol. 2015 Jan 1;93(1):1-10. doi: 10.1016/j.bcp.2014.11.008. Epub 2014 Dec 4. Review. PubMed PMID: 25481298. 3. Zhang Y, et al. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res. 2020 Nov;289:198167. 4. Wolf MC, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3157-62. |